Niraparib tosylate hydrate (also known as MK-4827; MK4827; Zejula), the tosylate salt and hydrated form of niraparib, is a selective inhibitor of PARP1/2 (IC50 = 3.8 nM and 2.1nM) that was approved by FDA for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

纯度：≥98%

CAS：1613220-15-7